These two studies research the risk of infections [20] and lymphoma [21] associated with thiopurines and anti-tumor necrosis factor (TNF) agents, used alone or in combination, providing important evidence for the management of IBD. This evidence concerns the gene TNF and inflammatory bowel disease.